INOVIQ (ASX:IIQ) Announces CEO Transition as Chairman Peter Gunzburg Steps Into Executive Role

Sonal Goyal

23 October 2026 12:23 PM AEDT

INOVIQ (ASX:IIQ) Announces CEO Transition as Chairman Peter Gunzburg Steps Into Executive Role

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

CEO Dr Leearne Hinch will step down on 27 October 2026 under a mutual agreement with the Board.
Chairman Peter Gunzburg becomes interim Executive Chair with no additional remuneration during the CEO search.
INOVIQ now has 2 products in market, 2 in later-stage development and 1 in early development.
The company will update the market on its future plans at the Annual General Meeting on 25 November 2026.

INOVIQ Limited (ASX:IIQ), a Melbourne-based biotechnology company developing exosome-based diagnostics and therapeutics, has announced a planned leadership transition. The Board and Chief Executive Officer Dr Leearne Hinch have mutually agreed that she will step down from the role on 27 October 2026, four days after the announcement dated 23 October 2026.

The company describes the change as planned, and it follows a 10-year period over which Dr Hinch contributed to the business, according to the Chairman. The Board has not named a permanent successor and says it will advise the market of an appointment in due course. The announcement carries statements from both the Chairman and the outgoing CEO, and both refer to the foundations built during her tenure.

Interim Arrangements at the Top

Chairman Peter Gunzburg will assume the role of Executive Chair on an interim basis. The company states that he will receive no additional remuneration for taking on the executive responsibilities, so the interim arrangement does not add to executive pay while the position is vacant.

During the interim period, the company will conduct an executive search for a new CEO. No timetable for the search or for an appointment was given beyond the commitment to inform the market when one is made. Mr Gunzburg remains the contact for further information on the matter.

The arrangement places the Board's chair in an executive position, so the chair and executive functions sit with one person until a chief executive is recruited. The announcement describes the Executive Chair role as interim, and ties its length to the outcome of the executive search.

A Decade of Development Under Dr Hinch

Mr Gunzburg credited Dr Hinch with a significant contribution to INOVIQ's development over the past 10 years. In his words, the business has evolved from a single-asset, early-stage technology into a company with two products in market, two products in later-stage development and one in early development.

The Board said it remains confident in the foundations established for INOVIQ's next phase, and thanked Dr Hinch for her leadership, commitment and contributions.

Dr Hinch described leading INOVIQ through its transformation into an exosome diagnostics and therapeutics company as a privilege. She thanked her executive team and colleagues for their contributions and said she was proud of what had been achieved in advancing the business toward important development and commercialisation milestones. She added that she is confident the company and its team will continue to build on those foundations and realise its potential.

The Product Portfolio and Corporate Timetable

INOVIQ's published company profile outlines the range of products behind the portfolio count cited by the Chairman. The commercial-stage offering consists of exosome isolation products. The clinical-stage program is a diagnostic intended for the early detection of ovarian cancer. The preclinical program is a CAR-exosome therapeutic aimed at treating tumours. The company says it is shaping the future of cancer detection and treatment with the aim of improving patient outcomes. In its own description, INOVIQ is a leader in exosome technology advancing next-generation diagnostics and therapeutics that transform cancer care.

The company has also completed its recent review. It says it will update the market on its plans for the future at the Annual General Meeting, which is scheduled for 25 November 2026. The announcement does not set out the findings of that review, and it does not give financial figures, so the Annual General Meeting is the next date the company has attached to a fuller update.

The announcement was authorised for release by the INOVIQ Limited Board of Directors and lists the company's address as 23 Normanby Road, Notting Hill, Victoria.

Summing Up the Leadership Change

The facts disclosed are limited but specific. Dr Hinch departs on 27 October 2026 by mutual agreement, Mr Gunzburg moves into an interim executive role without further pay, an executive search is under way, and a broader update on company plans is set for 25 November 2026. The company reports a portfolio of five products, two of them already in market and two in later-stage development, with the remaining one at an early stage. Together with the Annual General Meeting date, these details set out the immediate shape of INOVIQ's governance and corporate communication.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.